Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could laughing gas lift depression in seniors?

NCT ID NCT05007028

Symptom relief Sponsor: University Hospital, Tours Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a one-hour dose of nitrous oxide (laughing gas) can quickly reduce depression symptoms in adults aged 60-90 whose depression hasn't improved with standard treatments. Sixty participants received either the gas or medical air, and their mood was tracked over two weeks. The goal was to see if this safe, fast-acting approach could offer relief for late-life depression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Nitrous oxide (laughing gas) mixed with oxygen
What this could lead to
If it works, this could offer a fast-acting, short-term option to relieve depression in older adults who haven't found relief from standard antidepressants.
What could go wrong
This is a small, early-stage study with only 60 participants. The effects may be temporary, and not everyone responds. Side effects like nausea or dizziness are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Nov 2021

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 60-90 years-old * Major Depressive Episode according to DSM-5 criteria, confirmed by the MINI - Mini International Neuropsychiatric Interview * MADRS score greater than 20 (Montgomery Asberg Depression Rating Scale) * Patient resistant to at least one well-conducted antidepressant treatment, as documented by the MGH-ATRQ scale * Patient who can undergo N2O diffusion via a facial mask * Patient who has signed an informed consent * Person affiliated with a social security scheme Exclusion Criteria: * Bipolar disorder, schizophrenic disorder, neurodegenerative disease, documented by the MINI and the MMSE (non-inclusion if MMSE \< 24/30), addictive disorder * Unstable somatic pathology (including unstable neurological or cardiological diseases at risk of interfering with N2O diffusion) * Presence of active and significant psychotic symptoms, at investigator's discretion * Contraindications to EMONO (50%N2O/ 50%O2) : pneumothorax, emphysema, bowel obstruction, intracranial hypertension, chronic deficiency in vitamin B12 or B9 * Contraindications to MRI, including claustrophobia * Legal incapacity and/or other circumstances unabling the patient to understand the nature, purpose or consequences of the study * A person participating in a drug clinical trial or during a period of exclusion from any clinical study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Late life depression are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Depressive Disorder, Treatment-Resistant major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Late life depression Resistant depression, treatment

Contacts and locations

Locations

  • University Hospital of Tours

    Tours, 37044, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.